Severe acute respiratory syndrome coronavirus elicits a weak interferon response compared to traditional interferon-inducing viruses.
The aim of the present study is to investigate changes of interferon (IFN) production occurring over the first 48 h after infection of peripheral blood mononuclear cells (PBMCs) with severe acute respiratory syndrome (SARS) coronavirus (CoV) and to compare these changes to those induced by well-established IFN-inducing viruses, such as vesicular stomatitis (VSV) and Newcastle viruses (NDV). Experiments have been carried out using PBMCs of 10 different healthy donors. The results showed that the antiviral activity of IFN contained in the supernatant of SARS-CoV-infected PBMCs was lower than those induced by VSV and NDV. Consequently, SARS-CoV induces a lower synthesis of IFN-alpha, -beta and -gamma compared to VSV and NDV. Characterization of the profile of IFN-alpha subtypes genes expression in SARS-CoV-infected PBMCs demonstrated that the level of IFN-alpha2 and -6 subtypes were higher compared to other IFN-alpha subtypes namely, IFN-alpha5, -8, -10, -13/1, -17, and -21. In conclusion, SARS-CoV induces IFNs to a less extent compared to VSV and NDV, thus suggesting that the IFN system does play a limited role in early host defense against SARS-CoV infection.
Scagnolari
Carolina
C
Department of Experimental Medicine - Virology Section, Sapienza University of Rome, Rome, Italy. carolina.scagnolari@uniroma1.it
Trombetti
Simona
S
Cicetti
Simona
S
Antonelli
Silvia
S
Selvaggi
Carla
C
Perrone
Lorena
L
Visca
Michela
M
Romano
Sara
S
Antonelli
Guido
G
D002478:Cells, Cultured; D020869:Gene Expression Profiling; D006801:Humans; D007372:Interferons / Q000096:biosynthesis / Q000276:immunology*; D007963:Leukocytes, Mononuclear / Q000276:immunology* / Q000821:virology*; D009522:Newcastle disease virus / Q000276:immunology; D045473:Severe acute respiratory syndrome-related coronavirus / Q000276:immunology*; D018116:Vesiculovirus / Q000276:immunology
D007372:Interferons
Biochem Biophys Res Commun. 1983 Apr 29;112(2):537-46
6303322
Virol J. 2006 Mar 29;3:17
16571117
J Interferon Res. 1993 Dec;13(6):423-6
8151137
PLoS Pathog. 2007 Aug 10;3(8):e112
17696609
Biochimie. 2007 Jun-Jul;89(6-7):836-42
17336442
J Viral Hepat. 2001 Mar;8(2):103-10
11264730
Virology. 2005 Oct 10;341(1):163-9
16095648
Biochimie. 2007 Jun-Jul;89(6-7):713-8
17544197
J Interferon Cytokine Res. 1996 Dec;16(12):1027-33
8974005
J Virol. 2005 May;79(10):6180-93
15858003
Virology. 2007 Apr 25;361(1):18-26
17316733
Arch Biochem Biophys. 1981 Aug;210(1):319-29
6170263
J Gen Virol. 2006 Jul;87(Pt 7):1953-1960
16760397
Hepatol Res. 2002 Oct;24(2):99
12270738
J Virol. 2005 Jun;79(12):7819-26
15919935
BMC Infect Dis. 2004 Sep 09;4:34
15357874
Virus Res. 2008 Apr;133(1):101-12
17451827
J Med Virol. 2006 Apr;78(4):417-24
16482545
Virus Res. 2005 Jan;107(1):93-101
15567038
J Immunol Methods. 2003 May 1;276(1-2):207-22
12738374
Hepatol Res. 2006 Jan;34(1):41-9
16364683
J Virol. 2005 Feb;79(4):2079-86
15681410
Biochem J. 1998 Jan 15;329 ( Pt 2):295-302
9425112
Virus Res. 2008 Apr;133(1):13-9
17374415
Proc Natl Acad Sci U S A. 2006 Aug 22;103(34):12885-90
16912115
Emerg Infect Dis. 2004 Mar;10(3):413-8
15109406
Blood. 2005 Oct 1;106(7):2366-74
15860669
J Virol. 2007 Jan;81(2):548-57
17108024
Ann N Y Acad Sci. 2007 Apr;1102:26-38
17470909
Microbiol Immunol. 2006;50(1):19-24
16428869
Novartis Found Symp. 2006;279:56-60; discussion 60-5, 216-9
17278385
World J Gastroenterol. 2005 Aug 28;11(32):5037-43
16124062
J Virol. 2005 Nov;79(21):13800-5
16227300